Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone858-875-8600
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees132
OptionableNot Optionable
Orexigen Therapeutics (NASDAQ:OREX) Frequently Asked Questions
What is Orexigen Therapeutics' stock symbol?
Orexigen Therapeutics trades on the NASDAQ under the ticker symbol "OREX."
How were Orexigen Therapeutics' earnings last quarter?
Orexigen Therapeutics, Inc. (NASDAQ:OREX) posted its quarterly earnings results on Monday, November, 13th. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, topping analysts' consensus estimates of ($2.13) by $0.78. The biopharmaceutical company had revenue of $18.90 million for the quarter, compared to analyst estimates of $24.20 million. The business's revenue was up 170.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.12 earnings per share. View Orexigen Therapeutics' Earnings History.
What price target have analysts set for OREX?
1 Wall Street analysts have issued twelve-month price objectives for Orexigen Therapeutics' shares. Their forecasts range from $0.02 to $0.02. On average, they anticipate Orexigen Therapeutics' stock price to reach $0.02 in the next year. This suggests that the stock has a possible downside of 91.0%. View Analyst Price Targets for Orexigen Therapeutics.
What is the consensus analysts' recommendation for Orexigen Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orexigen Therapeutics in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell." View Analyst Ratings for Orexigen Therapeutics.
Has Orexigen Therapeutics been receiving favorable news coverage?
Media stories about OREX stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Orexigen Therapeutics earned a news impact score of 1.7 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the stock's share price in the next few days.
Who are some of Orexigen Therapeutics' key competitors?
Some companies that are related to Orexigen Therapeutics include Advanced Accelerator Application (AAAP), American Oriental Bioengineering (AOBI), Aralez Pharmaceuticals (ARLZ), ARMO Biosciences (ARMO), Bohai Pharmaceuticals Group (BOPH), Cardiome Pharma (CRME), Concordia International (CXRXD), Concordia International (CXRX), Depomed (DEPO), Egalet (EGLT), Eleven Biotherapeutics (EBIO), Impax Laboratories (IPXL), Juniper Pharmaceuticals (JNP), Oncolytics Biotech (ONCYF) and Pivotal Therapeutics (PVTTF).
Who are Orexigen Therapeutics' key executives?
Orexigen Therapeutics' management team includes the folowing people:
- Mr. Michael A. Narachi, Pres, Chief Exec. Officer & Director (Age 59)
- Dr. Thomas R. Cannell D.V.M., Exec. VP, COO & Pres of Global Commercial Products (Age 56)
- Mr. Thomas P. Lynch, Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec. (Age 51)
- Ms. Monica Forbes, VP & Acting CFO (Age 42)
- Mr. Stephen A. Moglia, Chief Accounting Officer, VP and Controller (Age 53)
How do I buy shares of Orexigen Therapeutics?
Shares of OREX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Orexigen Therapeutics' stock price today?
One share of OREX stock can currently be purchased for approximately $0.2229.
What is Orexigen Therapeutics' official website?
How can I contact Orexigen Therapeutics?
Orexigen Therapeutics' mailing address is 3344 N. TORREY PINES CT. SUITE 200, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-875-8600 or via email at [email protected]
MarketBeat Community Rating for Orexigen Therapeutics (NASDAQ OREX)
MarketBeat's community ratings are surveys of what our community members think about Orexigen Therapeutics and other stocks. Vote "Outperform" if you believe OREX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OREX will underperform the S&P 500 over the long term. You may vote once every thirty days.
